The NCCN Oncology Research Program (ORP) strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research. Since the program’s establishment in 1999, the NCCN ORP has brought millions of dollars in research grants to investigators at NCCN Member Institutions. Research grants are provided to NCCN through collaborations with pharmaceutical and biotechnology companies; these grants are in turn used to support scientifically meritorious cancer research efforts.
NCCN ORP studies typically explore new avenues of clinical investigation and seek answers to important cancer-related questions. All studies are approved and funded through a scientific peer-review process and are overseen by the ORP.
This feature highlights an NCCN study funded through the grant mechanism.
A Phase II Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor–Naïve Advanced EGFR-Mutant Lung Cancer
Principal Investigator: Pasi Janne, MD
Condition: Non–small cell lung cancer
Institution: Dana-Farber Cancer Institute
This phase II clinical trial is studying a combination of 2 targeted therapies as a possible treatment for non–small cell lung cancer (NSCLC) with an EGFR mutation. Osimertinib alone has been shown to benefit some patients who have received prior treatment for their EGFR-mutant NSCLC. Selumetinib is to be administered orally intermittently (4 days on, 3 days off), and osimertinib is to be administered orally on a daily basis. The main purpose of the study is to evaluate information on any potential side effects that this drug combination may cause and collect data on how NSCLC responds to the combination of drugs. Specific tyrosine kinase inhibitors have been approved by the FDA for first-line treatment of patients with NSCLC with an EGFR mutation.